Many different diseases fall under the umbrella of cardiovascular disease, and the causes range from structural defects to infection, inflammation, environmental, and genetics. As a result, cardiovascular drug development programs are complex and often require multidisciplinary research.
Charles River understands the challenges associated with developing a drug, biologic, or device for the prevention or treatment of cardiovascular diseases, as well as the importance of assessing potential undesirable cardiac effects for any new compound regardless of the disease target or condition. We have a long history of providing a multitude of products and services through our Research Models, Preclinical, and Clinical businesses to support you from early discovery to market.
Products & Services
- Preclinical cardiovascular screening and profiling
- Conscious and anesthetized models
- Telemetry
- Dedicated surgical suites
- In vitro and in vivo assessments
- Research disease models
- hERG assay
- Echocardiography
- Fluoroscopy
- Safety and efficacy studies
- Standard and specialized routes of administration
- Formulation development, preparation, and analysis
- Early-phase clinical trials
- All therapeutic indications
- All routes of delivery
- Continuous telemetry
- Digital ECG capture
- QT studies
- Pathology services
- Scientific and regulatory consulting